Shenzhen New Industries Adjusts Valuation Amid Financial Performance Challenges

Shenzhen New Industries Biomedical Engineering Co., Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. The company's valuation score has been revised, reflecting a shift in its financial metrics and market position. Currently, the stock exhibits a P/E ratio of 32, which suggests a higher valuation compared to its peers. The Price to Book Value stands at 6.46, indicating a premium on the stock relative to its book value. Additionally, the EV to EBIT and EV to EBITDA ratios are recorded at 29.85 and 26.35, respectively, which further emphasizes the company's valuation dynamics. Despite a dividend yield of 1.90%, the company has faced challenges in its financial performance, particularly in the quarter ending September 2025, where it reported negative results. The ROCE has reached a low of 19.56%, and the debt-equity ratio has shown a significant increase. Over the past year, the stock has generated a return of -6.12%, with profits declining by 6.5%. These factors contribute to the current evaluation adjustment for Shenzhen New Industries Biomedical Engineering Co., Ltd., highlighting the complexities of its financial landscape. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.